AirSculpt reaches this second quarter in the middle of its hardest stretch since going public: the surgical body-contouring chain that once grew to nearly $196 million in revenue and a 22% adjusted margin has spent two years watching weight-loss drugs hollow out demand for its procedures. Revenue fell more than 15% last year, the stock lost roughly 85% of its value from October 2025 to February 2026, and the balance sheet was restructured twice just to keep the debt current. The question the market is asking is whether this is a company stabilizing around a lower but durable run-rate, or a base that keeps eroding as pharmacology improves. The second quarter supplied evidence for both readings.
The argument for stabilization is real and runs through the case counts. Same-center case volume rose 1.0% in the quarter - a second consecutive quarter of growth on the metric management itself watches - and same-center revenue was essentially flat year to date. Company-wide revenue fell 2.5% in the quarter and just 1.3% in the first half, a dramatic narrowing from the 16% decline booked in fiscal 2025. Management frames it as "the second quarter of stability," stepped up its marketing investment, and signed an exclusive deal with an injectable-fat partner to broaden its procedure mix. The stock, at $3.21, has more than doubled off its February low.
The argument against is just as concrete and it lives in the profit line. The same quarter that showed the volume inflection carried a 15% drop in adjusted EBITDA, a jump in customer-acquisition costs from roughly $2,905 to $3,467 per case, and a guidance cut: full-year adjusted EBITDA was lowered to $12–14 million from a prior range. The stabilization in cases is being bought, not banked - the volume turned while profitability kept sliding. That divergence, stabilization of demand against erosion of margin, is the whole investment debate, and it is exactly what the next two quarters will resolve.